Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$13.38
+18.2%
$9.11
$5.00
$16.85
$662.58M1.481.45 million shs3.62 million shs
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$5.47
$5.47
$5.47
$352.00
$127.45M2.46279 shsN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$10.29
-3.0%
$9.89
$6.42
$29.60
$563.28M1.07293,047 shs233,324 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.58
-1.3%
$9.62
$5.45
$13.16
$641.39M1.97741,356 shs720,409 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+11.60%+14.03%+32.49%+50.23%-15.46%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+2.12%-2.75%+14.95%+12.04%-46.22%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-2.82%-8.29%+29.76%+60.47%+93.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
0.6914 of 5 stars
1.01.00.00.02.52.50.6
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
3.1138 of 5 stars
3.55.00.00.01.23.30.0
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.2654 of 5 stars
3.65.00.00.03.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
2.00
Hold$8.50-36.48% Downside
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00
N/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
3.00
Buy$30.83199.64% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.11
Buy$23.71104.79% Upside

Current Analyst Ratings Breakdown

Latest PFSCF, TYRA, DNA, and ZVRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.00
7/2/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$26.00
7/1/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/21/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$33.00
5/14/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/14/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$227.04M3.45N/AN/A$13.17 per share1.02
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$36.55M3.49N/AN/A($67.63) per share-0.08
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$6.78 per shareN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$23.61M26.82N/AN/A$0.74 per share15.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
-$150.73MN/A0.00N/A-894.02%-3,350.55%-67.76%N/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$86.48M-$1.630.00N/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$105.51M-$1.900.0057.90N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)

Latest PFSCF, TYRA, DNA, and ZVRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.44N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$0.65N/AN/AN/A$22.49 millionN/A
8/6/2025Q2 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.53N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million
5/8/2025Q1 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.49-$0.47+$0.02-$0.47N/AN/A
5/6/2025Q1 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.88
4.88
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
0.95
0.71
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
22.78
22.78
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
1.46
3.02
2.93

Institutional Ownership

CompanyInstitutional Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.10%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
9.72%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
15.20%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64058.53 million52.84 millionOptionable
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
5023.31 millionN/ANot Optionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2053.09 million45.02 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2054.68 million53.37 millionOptionable

Recent News About These Companies

Q2 EPS Forecast for Zevra Therapeutics Boosted by Analyst
William Blair Issues Optimistic Forecast for ZVRA Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$13.38 +2.06 (+18.21%)
Closing price 03:58 PM Eastern
Extended Trading
$13.64 +0.26 (+1.97%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

ProMetic Life Sciences stock logo

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)
As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$10.29 -0.32 (-3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$10.28 -0.01 (-0.15%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$11.58 -0.15 (-1.28%)
Closing price 04:00 PM Eastern
Extended Trading
$11.80 +0.22 (+1.93%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.